A nurse is caring for a client with end-stage renal disease (ESRD) on hemodialysis who has developed secondary hyperparathyroidism. The client's laboratory results show: serum calcium 7.8 mg/dL (normal: 8.5-10.5 mg/dL), serum phosphorus 6.2 mg/dL (normal: 2.5-4.5 mg/dL), and intact parathyroid hormone (iPTH) 450 pg/mL (normal: 10-65 pg/mL). Which nursing intervention should be the priority?

Severe hypocalcemia (Ca 7.8 mg/dL) with symptoms like muscle cramps poses immediate risks of tetany and seizures, requiring priority monitoring and safety precautions. Other options are important but address less urgent aspects of management.

Understanding the Pathophysiology
In end-stage renal disease (ESRD), the kidneys lose the ability to activate vitamin D and excrete phosphorus. This leads to a cascade of events driving secondary hyperparathyroidism (SHPT). The failing kidneys cannot excrete phosphorus, causing serum phosphorus to rise (6.2 mg/dL). Elevated phosphorus binds to calcium, which directly lowers free, ionized calcium levels. Simultaneously, the kidneys produce less active vitamin D (calcitriol), which is necessary for calcium absorption from the gut. The resulting hypocalcemia (7.8 mg/dL) is a powerful, persistent stimulus for the parathyroid glands to secrete parathyroid hormone (PTH). The markedly elevated intact parathyroid hormone (iPTH) level of 450 pg/mL confirms the diagnosis of severe SHPT. This condition creates a state of high bone turnover as PTH leaches calcium from the bones to correct the low serum calcium, causing bone pain and predisposing the patient to fractures.

Priority Nursing Assessment and Intervention
The priority intervention is to monitor for signs of tetany and implement seizure precautions. This decision is driven by the immediate physiological threat posed by the client's severe hypocalcemia. The serum calcium level of 7.8 mg/dL is significantly below the normal range, and the client is already exhibiting classic neuromuscular irritability symptoms, including muscle cramps and a subjective report of anxiety with difficulty concentrating. These are prodromal signs of more severe complications.

Hypocalcemia increases the excitability of neuronal membranes by lowering the threshold potential, making them more likely to fire spontaneously. This manifests first as paresthesias and muscle cramps, but can rapidly progress to tetany (involuntary muscle contractions), laryngospasm, and generalized seizures. The client's anxious state is not merely psychological; it is a direct neurological manifestation of severe electrolyte imbalance. A patient on hemodialysis with SHPT is at high risk for acute decompensation, and seizure precautions are a non-invasive, high-impact safety measure that must be established immediately to prevent injury while definitive pharmacological treatments are prepared and administered. The association between psychological symptoms like anxiety and physiological instability in dialysis patients is significant, as studies have shown that such symptoms can co-occur with serious intradialytic complications, making their presence a critical clinical cue for underlying instability ^[1].

Analysis of Incorrect Options

Option 1: Administer calcium carbonate as prescribed to increase serum calcium levels.
While administering a calcium-based phosphate binder like calcium carbonate is a standard, long-term strategy for managing both hypocalcemia and hyperphosphatemia in SHPT, it is not the immediate priority. This medication must be given with meals to bind dietary phosphorus in the gut, and its effect on serum calcium is gradual. Before administering any calcium supplement, the nurse must first ensure the client's immediate safety from the life-threatening neurological effects of the current severe hypocalcemia. A large-scale study on SHPT management notes that pharmacological interventions like calcimimetics are used for long-term control of severe disease, but the acute bedside priority remains the patient's clinical presentation and immediate risk ^[3].

Option 2: Encourage increased dietary intake of dairy products and leafy green vegetables.
This intervention is contraindicated. Dairy products are extremely high in phosphorus. In ESRD, the primary dietary goal is phosphorus restriction to manage the driving force behind SHPT. While leafy green vegetables are generally healthy, many contain high amounts of phosphorus or potassium, which must also be restricted. The client's serum phosphorus is already dangerously high at 6.2 mg/dL. Increasing dietary phosphorus would worsen the calcium-phosphorus imbalance, further stimulate PTH secretion, and accelerate renal osteodystrophy and vascular calcification. Nutritional strategies in dialysis patients are focused on achieving a delicate balance, and a systematic review emphasizes that interventions are designed to combat protein-energy wasting without exacerbating electrolyte imbalances, making a blanket recommendation for high-phosphorus foods unsafe ^[2].

Option 4: Restrict phosphorus intake by eliminating all protein sources from the diet.
This is a dangerous and incorrect recommendation. While dietary phosphorus restriction is a cornerstone of SHPT management, it must be done intelligently. Phosphorus is primarily found in protein-containing foods. Eliminating all protein sources would lead to severe protein-energy wasting (PEW), a devastating complication in dialysis patients that is strongly associated with increased morbidity, mortality, and poorer quality of life ^[2]. A meta-analysis on malnutrition in dialysis patients highlights the critical need for accurate risk prediction to prevent PEW, underscoring that nutritional management must be precise, not based on total elimination of essential macronutrients ^[4]. The correct approach is to counsel the patient on choosing high-biological-value proteins and effectively using phosphate binders with meals, a complex task that is not the immediate safety priority.